Flexion Therapeutics (NASDAQ:FLXN)‘s stock had its “outperform” rating restated by equities researchers at BMO Capital Markets in a report released on Friday. They currently have a $36.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $37.00. BMO Capital Markets’ target price would suggest a potential upside of 34.68% from the company’s previous close.
FLXN has been the subject of several other research reports. BidaskClub downgraded Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 20th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Flexion Therapeutics in a research report on Friday, November 10th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. Finally, Berenberg Bank began coverage on Flexion Therapeutics in a research report on Thursday, February 1st. They issued a “buy” rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $99.00.
Shares of Flexion Therapeutics (FLXN) opened at $26.73 on Friday. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $993.06, a PE ratio of -6.50 and a beta of 0.73.
Several large investors have recently added to or reduced their stakes in FLXN. Advisory Services Network LLC acquired a new position in shares of Flexion Therapeutics in the fourth quarter worth about $108,000. SG Americas Securities LLC acquired a new position in shares of Flexion Therapeutics in the third quarter worth about $135,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Flexion Therapeutics in the third quarter worth about $235,000. Teacher Retirement System of Texas acquired a new position in shares of Flexion Therapeutics in the fourth quarter worth about $245,000. Finally, Voya Investment Management LLC lifted its stake in shares of Flexion Therapeutics by 25.8% in the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock worth $261,000 after acquiring an additional 2,651 shares in the last quarter. Institutional investors and hedge funds own 94.71% of the company’s stock.
WARNING: This report was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3254401/flexion-therapeutics-flxn-given-outperform-rating-at-bmo-capital-markets.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.